Cabaletta Bio (CABA) Common Equity (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Common Equity of $112.1 million for Q4 2025, down 26.44% year-over-year from $152.3 million in Q4 2024, and down 19.66% quarter-over-quarter from $139.5 million in Q3 2025.
Cabaletta Bio (CABA) Common Equity (2018 - 2026) Analysis & Trends
Cabaletta Bio's Common Equity history runs 8 years deep, the most recent figure standing at $112.1 million for Q4 2025.
- In Q4 2025, Common Equity fell 26.44% year-over-year to $112.1 million; the TTM figure through Dec 2025 stood at $112.1 million (down 26.44% YoY), while the FY2025 annual figure was $112.1 million, down 26.44% from the prior year.
- Common Equity for Q4 2025 stood at $112.1 million, down from $139.5 million in the prior quarter.
- The five-year high for Common Equity was $236.2 million in Q4 2023, with the low at $85.9 million in Q3 2022.
- The 5-year median for Common Equity is $119.8 million (2021), against an average of $139.7 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity soared 141.92% in 2024, then plunged 45.18% in 2025.
- Cabaletta Bio's Common Equity stood at $118.0 million in 2021, then retreated by 11.39% to $104.5 million in 2022, then soared by 125.98% to $236.2 million in 2023, then tumbled by 35.51% to $152.3 million in 2024, then decreased by 26.44% to $112.1 million in 2025.
- Business Quant data shows CABA's Common Equity at $112.1 million in Q4 2025, $139.5 million in Q3 2025, and $178.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 210.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 210.59 Mn |
| Dec 31, 2025 | 112.05 Mn |
| Sep 30, 2025 | 139.47 Mn |
| Jun 30, 2025 | 178.48 Mn |
| Mar 31, 2025 | 121.55 Mn |
| Dec 31, 2024 | 152.34 Mn |
| Sep 30, 2024 | 174.24 Mn |
| Jun 30, 2024 | 199.52 Mn |
| Mar 31, 2024 | 221.72 Mn |
| Dec 31, 2023 | 236.20 Mn |
| Sep 30, 2023 | 160.92 Mn |
| Jun 30, 2023 | 174.14 Mn |
| Mar 31, 2023 | 91.65 Mn |
| Dec 31, 2022 | 104.52 Mn |
| Sep 30, 2022 | 85.87 Mn |
| Jun 30, 2022 | 95.53 Mn |
| Mar 31, 2022 | 106.72 Mn |
| Dec 31, 2021 | 117.96 Mn |
| Sep 30, 2021 | 116.62 Mn |
| Jun 30, 2021 | 101.33 Mn |